Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Urology

Journal Scan / Research · August 31, 2022

Outcomes of Enzalutamide Monotherapy With Active Surveillance in Patients With Low-Risk or Intermediate-Risk Localized Prostate Cancer

JAMA Oncology

 

 Save  Recommend
 Share

Additional Info

JAMA Oncology
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial
JAMA Oncol 2022 Aug 01;8(8)1128-1136, ND Shore, J Renzulli, NE Fleshner, CMP Hollowell, S Vourganti, J Silberstein, R Siddiqui, J Hairston, D Elsouda, D Russell, MR Cooperberg, SA Tomlins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Recently Updated